Literature DB >> 23386736

MR imaging of primary sclerosing cholangitis: additional value of diffusion-weighted imaging and ADC measurement.

Jelena Djokić Kovač1, Rada Ješić, Dejana Stanisavljević, Bojan Kovač, Ružica Maksimovic.   

Abstract

BACKGROUND: Primary sclerosing cholangitis (PSC) is a cholestatic liver disease with chronic inflammation and progressive destruction of biliary tree. Magnetic resonance (MR) examination with diffusion-weighted imaging (DWI) allows analysis of morphological liver parenchymal changes and non-invasive assessment of liver fibrosis. Moreover, MR cholangiopancreatography (MRCP), as a part of standard MR protocol, provides insight into bile duct irregularities.
PURPOSE: To evaluate MR and MRCP findings in patients with primary sclerosing cholangitis and to determine the value of DWI in the assessment of liver fibrosis.
MATERIAL AND METHODS: The following MR findings were reviewed in 38 patients: abnormalities in liver parenchyma signal intensity, changes in liver morphology, lymphadenopathy, signs of portal hypertension, and irregularities of intra- and extrahepatic bile ducts. Apparent diffusion coefficient (ADC) was calculated for six locations in the liver for b = 800 s/mm(2).
RESULTS: T2-weighted hyperintensity was seen as peripheral wedge-shaped areas in 42.1% and as periportal edema in 28.9% of patients. Increased enhancement of liver parenchyma on arterial-phase imaging was observed in six (15.8%) patients. Caudate lobe hypertrophy was present in 10 (26.3%), while spherical liver shape was noted in 7.9% of patients. Liver cirrhosis was seen in 34.2% of patients; the most common pattern was micronodular cirrhosis (61.5%). Other findings included lymphadenopathy (28.9%), signs of portal hypertension (36.7%), and bile duct irregularities (78.9%). The mean ADCs (x10(-3)mm(2)/s) were significantly different at stage I vs. stages III and IV, and stage II vs. stage IV. No significant difference was found between stages II and III. For prediction of stage ≥II and stage ≥III, areas under receiver-operating characteristic curves were 0.891 and 0.887, respectively.
CONCLUSION: MR with MRCP is a necessary diagnostic procedure for diagnosis of PSC and evaluation of disease severity. Moreover, DWI could be used in continuation with standard MR sequences for the evaluation of liver fibrosis stage and distribution.

Entities:  

Mesh:

Year:  2013        PMID: 23386736     DOI: 10.1177/0284185112471792

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  9 in total

1.  Comparison of diffusion-weighted imaging and MR elastography in staging liver fibrosis: a meta-analysis.

Authors:  Weon Jang; Seongil Jo; Ji Soo Song; Hong Pil Hwang; Seong-Hun Kim
Journal:  Abdom Radiol (NY)       Date:  2021-03-26

2.  MR imaging and MR cholangiopancreatography of cholangiocarcinoma developing in printing company workers.

Authors:  Koichi Koyama; Shoji Kubo; Ai Ueki; Taro Shimono; Shigekazu Takemura; Shogo Tanaka; Masahiko Kinoshita; Genya Hamano; Yukio Miki
Journal:  Jpn J Radiol       Date:  2017-03-02       Impact factor: 2.374

3.  Quantitative evaluation of hepatic fibrosis by fibro Scan and Gd-EOB-DTPA-enhanced T1 mapping magnetic resonance imaging in chronic hepatitis B.

Authors:  Qingtao Li; Tianyou Chen; Nannan Shi; Wen Ye; Min Yuan; Yuxin Shi
Journal:  Abdom Radiol (NY)       Date:  2021-11-25

Review 4.  MR elastography in primary sclerosing cholangitis: a pictorial review.

Authors:  Christopher L Welle; Patrick J Navin; Michael C Olson; Safa Hoodeshenas; Michael S Torbenson; Sudhakar K Venkatesh
Journal:  Abdom Radiol (NY)       Date:  2022-05-14

Review 5.  [Functional MR imaging of the liver].

Authors:  A Wibmer; R Nolz; M Trauner; A Ba-Ssalamah
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

6.  Diagnostic value of magnetic resonance parametric mapping for non-invasive assessment of liver fibrosis in patients with primary sclerosing cholangitis.

Authors:  Narine Mesropyan; Patrick Kupczyk; Guido M Kukuk; Leona Dold; Tobias Weismueller; Christoph Endler; Alexander Isaak; Anton Faron; Alois M Sprinkart; Claus C Pieper; Daniel Kuetting; Christian P Strassburg; Ulrike I Attenberger; Julian A Luetkens
Journal:  BMC Med Imaging       Date:  2021-04-07       Impact factor: 1.930

7.  Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group.

Authors:  Sudhakar K Venkatesh; Christopher L Welle; Frank H Miller; Kartik Jhaveri; Kristina I Ringe; John E Eaton; Helen Bungay; Lionel Arrivé; Ahmed Ba-Ssalamah; Aristeidis Grigoriadis; Christoph Schramm; Ann S Fulcher
Journal:  Eur Radiol       Date:  2021-08-06       Impact factor: 5.315

8.  Clinical guidelines for primary sclerosing cholangitis 2017.

Authors:  Hiroyuki Isayama; Susumu Tazuma; Norihiro Kokudo; Atsushi Tanaka; Toshio Tsuyuguchi; Takahiro Nakazawa; Kenji Notohara; Suguru Mizuno; Nobuhisa Akamatsu; Masahiro Serikawa; Itaru Naitoh; Yoshiki Hirooka; Toshifumi Wakai; Takao Itoi; Tomoki Ebata; Shinji Okaniwa; Terumi Kamisawa; Hiroki Kawashima; Atsushi Kanno; Keiichi Kubota; Masami Tabata; Michiaki Unno; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2018-06-27       Impact factor: 7.527

Review 9.  Modern imaging of cholangitis.

Authors:  Sarah Pötter-Lang; Ahmed Ba-Ssalamah; Nina Bastati; Alina Messner; Antonia Kristic; Raphael Ambros; Alexander Herold; Jacqueline C Hodge; Michael Trauner
Journal:  Br J Radiol       Date:  2021-07-20       Impact factor: 3.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.